Maintenance is about what is tolerable and effective long term. If you can get extra immune and chemo activity, especially to dissolve lesions somewhere, that would be a plus. There are dramatic, published patients' success series with improved maintenance regimes, e.g. ADAPT (Xeloda + Celebrex). I was impressed with some mCRC ADAPT patients' stop and start performance, although we decided absolute treatment continuity would be more important to us, for 8 years. My wife has now been on immunochemo vacation for 11+ months. There may be types of patients where ADAPT out performs xeloda plus Avastin, as did some of Dr Lin's earlier published work.
Our idea of maintenance is to enhance chemo activity further than that, and to improve the tumor, immune, inflammation and liver parameters as much as possible. We used UFT+LV instead of Xeloda, and a lot of selected high potency supplements. Several years out, we added celecoxib and immune modulating supplements to the stack, saw an improvement in chemo activity and tumor markers. Site by site we've picked off lesions, chemically and surgically. However my chemistry comments are most grounded on the CA199 - RAS/BRAF mutant/mixed - CEA axis ( + CSLEX1), common but deadly metastatic types in the national statistics that might be fewer % here.
My view is that we need to get oncologists, MDs and NDs' combined efforts to increase their simple, targeted, generic chemistries performance at the individual patient's level, beyond current daily Xeloda based formulas and weak tea supplements. BC has clinics that might be good for that.
watchful, active researcher and caregiver for stage IVb/c CC. surgeries 4/10 sigmoid etc & 5/11 para-aortic LN cluster; 8 yrs immuno-Chemo for mCRC; now mostly IV C & no chemo
most of 2010 Life Extension recommendations and possibilities + more, some (much) higher, peaking ~2011-12, taper to almost nothing mid 2018